Role of inflammatory markers as hepatocellular cancer selection tool in the setting of liver transplantation

2007 ◽

Vol 89 (1) ◽

pp. 12-21 ◽

Cited By ~ 33

Author(s):

Mark D Stringer

Keyword(s):

Liver Transplantation ◽

Hepatocellular Cancer ◽

Good Prognosis ◽

Liver Tumours ◽

Primary Hepatic Malignancies ◽

Life Saving ◽

Time Of Presentation ◽

Benign Liver ◽

Hepatic Malignancies

In recent years, considerable progress has been made in the treatment of children with hepatoblastoma largely due to effective pre-operative chemotherapy. Total hepatectomy and liver transplantation has emerged as an effective treatment for the small proportion of children with unresectable hepatoblastoma limited to the liver. A 5-year survival of 70% can be achieved in such cases. In contrast, the results of liver transplantation in children with hepatocellular cancer remain poor because these tumours are usually advanced with evidence of major vascular invasion and/or extrahepatic spread at the time of presentation. An exception is those children in whom the hepatocellular carcinoma is detected during surveillance of chronic liver disease – they typically have smaller tumours and frequently have a good prognosis after liver transplantation. The role of liver transplantation in children with other primary hepatic malignancies remains uncertain because experience is very limited. Liver transplantation is rarely needed in the management of children with benign liver tumours but, if other treatments have failed, it can be a life-saving intervention.

Download Full-text

Recurrence of hepatocellular cancer after liver transplantation: The role of primary resection and salvage transplantation in East and West

Journal of Hepatology ◽

10.1016/j.jhep.2012.06.033 ◽

2012 ◽

Vol 57 (5) ◽

pp. 974-979 ◽

Cited By ~ 35

Author(s):

Quirino Lai ◽

Alfonso W. Avolio ◽

Jan Lerut ◽

Gurusharan Singh ◽

See Ching Chan ◽

...

Keyword(s):

Liver Transplantation ◽

Hepatocellular Cancer ◽

Primary Resection ◽

East And West

Download Full-text

Prognostic role of inflammatory markers in hepatocellular cancer patients receiving sorafenib therapy

Medical Science and Discovery ◽

10.36472/msd.v7i5.374 ◽

2020 ◽

Vol 7 (5) ◽

pp. 475-481

Author(s):

Ali Oğul ◽

Mahmut Büyükşimşek

Keyword(s):

Inflammatory Markers ◽

Prognostic Value ◽

Cox Regression ◽

Hepatocellular Cancer ◽

Prognostic Role ◽

Sorafenib Treatment ◽

Cox Regression Analysis ◽

Lymphocyte Ratio ◽

Tumor Focus

Objective: Systemic inflammatory markers have been shown to have prognostic value in many types of cancers. Although the prognostic role of the systemic immune-inflammation index (SII), derived neutrophil-lymphocyte ratio (dNLR) and platelet lymphocyte ratio (PLR) has been shown in hepatocellular cancer (HCC) patients who underwent transplantation, its prognostic value has not been investigated in HCC patients under sorafenib treatment. We investigated the prognostic value of inflammatory indices in patients with HCC under sorafenib treatment. Materials and Methods: The data of 46 patients with stage III unresectable and stage IV HCC were evaluated retrospectively. SII and dNLR were dichotomized based on receiver operating characteristic (ROC) curve analysis (cut-off values: 355 and 1.8). No cut-off value could be determined for PLR; therefore, the median value was defined as the cut-off for PLR. At the time of diagnosis, values of these three inflammatory markers were analyzed to determine their association with clinicopathologic characteristics and to assess their prognostic values via the Kaplan-Meier method and multivariate Cox regression analysis. Results: Overall survival (OS) was significantly shorter in patients with a high SII, dNLR, or PLR. In univariate analyses, tumor stage, tumor focus count, and presence of extrahepatic lesions seemed to affect survival. Multivariate analysis revealed SII and the presence of extrahepatic lesions as independent risk factors for survival. Conclusion: The findings of the present study suggest that a high SII is an independent risk factor for survival in patients with HCC under sorafenib treatment.

Download Full-text